To determine the economic benefits of IND/GLY compared with the free combination of indacaterol and glycopyrronium ( IND+GLY ) , and with the fixed-dose combination of salmeterol/fluticasone ( SFC ) , in a moderate-to-severe COPD population with low-exacerbation risk .